After receiving a personal invitation from President Susumu Takayangi MD, Global Stem Cells Group and its Korean biotechnology partner, N-Biotek, participated in the 23rd Congress of the International Society of Aesthetic Plastic Surgeons that took place this October in Kyoto. With the assistance of more than 1500 physicians and surgeons from around the globe, the conference’s focus was to grow a global understanding of the importance of the aesthetic modalities in plastic and reconstructive surgery and the applications of cellular and regenerative medicine in this field.
The Congress brought together an expert panel for a series of lectures and discussions that hope to provide solutions and create new techniques in the coming years to be applied in plastic and reconstructive surgery. Influential scientific and clinical experts stood together and evaluated the state of research and clinical application.
The keynote speaker in the conference was the Nobel Laureate Shinja Yamanaka. Dr Yamanaka won the award on 2012 for his creation of induced pluripotential stem cells. Yamanaka addressed among other things the importance of the regenerative medicine field opening a new frontier for the treatment of chronic degenerative conditions.
“We are excited to have attended the ISAPS conference once more. Our goal, as always, is to promote scientific training for physicians and research in stem cell technology that we hope will contribute to the global discussion on how these therapies can advance human health and longevity” says Benito Novas, founder and CEO.
Mr. Sanguk Ra, Business Director of N-Biotek, a biotechnology added ;”these are very exciting times, we see more and more physicians getting involved in regenerative medicine, and that of course puts more pressure on the scientists to help advance the field”
Both companies, as leaders of the industry, launched their new Turnkey Solution, a compact and cohesive laboratory as a concept for physicians’ offices, and the new Progenikine Kit, an enzyme based closed system for isolation of adipose derived stem cells. To learn more, visit the Global Stem Cells Group website, www.stemcellsgroup.com.
About Global Stem Cells Group:
Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions. With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine. Global Stem Cells Group’s corporate mission is to make the promise of stem cell medicine a reality for patients around the world. With each of GSCG’s six operating companies focused on a separate research-based mission, the result is a global network of state-of-the-art stem cell treatments.
